| Identification | Back Directory | [Name]
EGFRvIII peptide (PEPvIII) | [CAS]
129112-17-0 | [Synonyms]
EGFRvIII peptide (PEPvIII) | [Molecular Formula]
C70H111N19O24S | [MDL Number]
MFCD32068011 | [MOL File]
129112-17-0.mol | [Molecular Weight]
1634.83 |
| Chemical Properties | Back Directory | [Boiling point ]
2021.1±65.0 °C(Predicted) | [density ]
1.348±0.06 g/cm3(Predicted) | [pka]
2.83±0.10(Predicted) | [Sequence]
Leu-Glu-Glu-Lys-Lys-Gly-Asn-Tyr-Val-Val-Thr-Asp-His-Cys |
| Hazard Information | Back Directory | [Uses]
EGFRvIII peptide (PEPvIII) is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide represents a truly tumor-specific target for antitumor immunotherapy[1]. | [References]
[1] Schmittling RJ, et al. Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. J Immunol Methods. 2008 Nov 30;339(1):74-81. DOI:10.1016/j.jim.2008.08.004 |
|
| Company Name: |
Ontores Biotech
|
| Tel: |
0571-88760729 18072970094 |
| Website: |
www.ontoresinc.cn |
|